These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 25691693)

  • 1. Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas.
    van den Bent MJ; Gao Y; Kerkhof M; Kros JM; Gorlia T; van Zwieten K; Prince J; van Duinen S; Sillevis Smitt PA; Taphoorn M; French PJ
    Neuro Oncol; 2015 Jul; 17(7):935-41. PubMed ID: 25691693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in
    Felsberg J; Hentschel B; Kaulich K; Gramatzki D; Zacher A; Malzkorn B; Kamp M; Sabel M; Simon M; Westphal M; Schackert G; Tonn JC; Pietsch T; von Deimling A; Loeffler M; Reifenberger G; Weller M;
    Clin Cancer Res; 2017 Nov; 23(22):6846-6855. PubMed ID: 28855349
    [No Abstract]   [Full Text] [Related]  

  • 3. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients.
    Figueroa JM; Skog J; Akers J; Li H; Komotar R; Jensen R; Ringel F; Yang I; Kalkanis S; Thompson R; LoGuidice L; Berghoff E; Parsa A; Liau L; Curry W; Cahill D; Bettegowda C; Lang FF; Chiocca EA; Henson J; Kim R; Breakefield X; Chen C; Messer K; Hochberg F; Carter BS
    Neuro Oncol; 2017 Oct; 19(11):1494-1502. PubMed ID: 28453784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of EGFR gene amplification, protein over-expression and tyrosine kinase domain mutation in recurrent glioblastoma.
    Toth J; Egervari K; Klekner A; Bognar L; Szanto J; Nemes Z; Szollosi Z
    Pathol Oncol Res; 2009 Jun; 15(2):225-9. PubMed ID: 18752056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.
    Johnson H; Del Rosario AM; Bryson BD; Schroeder MA; Sarkaria JN; White FM
    Mol Cell Proteomics; 2012 Dec; 11(12):1724-40. PubMed ID: 22964225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas.
    Biernat W; Huang H; Yokoo H; Kleihues P; Ohgaki H
    Brain Pathol; 2004 Apr; 14(2):131-6. PubMed ID: 15193025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Evolution of
    Draaisma K; Chatzipli A; Taphoorn M; Kerkhof M; Weyerbrock A; Sanson M; Hoeben A; Lukacova S; Lombardi G; Leenstra S; Hanse M; Fleischeuer R; Watts C; McAbee J; Angelopoulos N; Gorlia T; Golfinopoulos V; Kros JM; Verhaak RGW; Bours V; van den Bent MJ; McDermott U; Robe PA; French PJ
    J Clin Oncol; 2020 Jan; 38(1):81-99. PubMed ID: 31743054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Alterations of Epidermal Growth Factor Receptor in Glioblastoma: The Usefulness of Immunohistochemistry.
    Lee M; Kang SY; Suh YL
    Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):589-598. PubMed ID: 29912767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
    Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
    Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification.
    Gupta A; Young RJ; Shah AD; Schweitzer AD; Graber JJ; Shi W; Zhang Z; Huse J; Omuro AM
    Clin Neuroradiol; 2015 Jun; 25(2):143-50. PubMed ID: 24474262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
    Keir ST; Chandramohan V; Hemphill CD; Grandal MM; Melander MC; Pedersen MW; Horak ID; Kragh M; Desjardins A; Friedman HS; Bigner DD
    J Neurooncol; 2018 Jul; 138(3):489-498. PubMed ID: 29564747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres.
    Patanè M; Porrati P; Bottega E; Morosini S; Cantini G; Girgenti V; Rizzo A; Eoli M; Pollo B; Sciacca FL; Pellegatta S; Finocchiaro G
    Mol Cancer; 2013 Dec; 12():160. PubMed ID: 24330732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation.
    Cardona AF; Jaramillo-Velásquez D; Ruiz-Patiño A; Polo C; Jiménez E; Hakim F; Gómez D; Ramón JF; Cifuentes H; Mejía JA; Salguero F; Ordoñez C; Muñoz Á; Bermúdez S; Useche N; Pineda D; Ricaurte L; Zatarain-Barrón ZL; Rodríguez J; Avila J; Rojas L; Jaller E; Sotelo C; Garcia-Robledo JE; Santoyo N; Rolfo C; Rosell R; Arrieta O
    J Neurooncol; 2021 Sep; 154(3):353-364. PubMed ID: 34498213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma.
    Fontanilles M; Marguet F; Ruminy P; Basset C; Noel A; Beaussire L; Viennot M; Viailly PJ; Cassinari K; Chambon P; Richard D; Alexandru C; Tennevet I; Langlois O; Di Fiore F; Laquerrière A; Clatot F; Sarafan-Vasseur N
    Acta Neuropathol Commun; 2020 Apr; 8(1):52. PubMed ID: 32303258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FHL2 interacts with EGFR to promote glioblastoma growth.
    Sun L; Yu S; Xu H; Zheng Y; Lin J; Wu M; Wang J; Wang A; Lan Q; Furnari F; Cavenee W; Purow B; Li M
    Oncogene; 2018 Mar; 37(10):1386-1398. PubMed ID: 29321665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
    Sepúlveda-Sánchez JM; Vaz MÁ; Balañá C; Gil-Gil M; Reynés G; Gallego Ó; Martínez-García M; Vicente E; Quindós M; Luque R; Ramos A; Ruano Y; Pérez-Segura P; Benavides M; Sánchez-Gómez P; Hernández-Laín A
    Neuro Oncol; 2017 Oct; 19(11):1522-1531. PubMed ID: 28575464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution and favorable prognostic implication of genomic EGFR alterations in IDH-wildtype glioblastoma.
    Higa N; Akahane T; Hamada T; Yonezawa H; Uchida H; Makino R; Watanabe S; Takajo T; Yokoyama S; Kirishima M; Matsuo K; Fujio S; Hanaya R; Tanimoto A; Yoshimoto K
    Cancer Med; 2023 Jan; 12(1):49-60. PubMed ID: 35695190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates.
    Kastenhuber ER; Huse JT; Berman SH; Pedraza A; Zhang J; Suehara Y; Viale A; Cavatore M; Heguy A; Szerlip N; Ladanyi M; Brennan CW
    Acta Neuropathol; 2014 May; 127(5):747-59. PubMed ID: 24292886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.
    O'Rourke DM; Nasrallah MP; Desai A; Melenhorst JJ; Mansfield K; Morrissette JJD; Martinez-Lage M; Brem S; Maloney E; Shen A; Isaacs R; Mohan S; Plesa G; Lacey SF; Navenot JM; Zheng Z; Levine BL; Okada H; June CH; Brogdon JL; Maus MV
    Sci Transl Med; 2017 Jul; 9(399):. PubMed ID: 28724573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.